EYDENZELT (aflibercept-boav)
EYDENZELT is indicated for the treatment of Neovascular Age-Related Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Diabetic Macular Edema; Diabetic Retinopathy.
Details
- Status
- Prescription
- First Approved
- 2025-10-02
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
EYDENZELT Approval History
What EYDENZELT Treats
5 indicationsEYDENZELT is approved for 5 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Neovascular Age-Related Macular Degeneration
- Macular Edema
- Retinal Vein Occlusion
- Diabetic Macular Edema
- Diabetic Retinopathy
EYDENZELT Target & Pathway
ProTarget
EYDENZELT is a lower-cost alternative to Eylea with no clinically meaningful differences. Requires prescriber approval to substitute.
EYDENZELT Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to EYDENZELT
3 of 11FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
EYDENZELT FDA Label Details
Indications & Usage
FDA Label (PDF)EYDENZELT is indicated for the treatment of Neovascular Age-Related Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Diabetic Macular Edema; Diabetic Retinopathy.
Track EYDENZELT with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.